- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
Systemic medications, particularly hydroxyl Chloroquine have the potential to cause retinal toxicity. We will review some of those medications and present two new medications for consideration. We’ll then review strategies for surveillance and management of toxicities.
Advanced in clinical and bench research in ophthalmology has produced multiple new treatment options for a variety of ocular diseases. New technology, including the fast growing field of ocular imaging, is been used to further understand eye anatomy and pathology. Progress in the field of ocular surgery has introduced new techniques and better outcomes. The clinical and research environment is complex; issues related to ethics, quality improvement and new technology affect all eye care providers. The Eye Institute has, as one of its mission, the goal of being at the forefront of research, clinical care and education. Our goal is to educate the academic and community eye care providers, residents, researchers and medical students on the best and newest clinical and surgical treatments, cutting edge research and important non-clinical topics available in the field.
- Community eye care professionals
- Full time faculty
- Fellow ophthalmologists
- Ophthalmic photographers
At the conclusion of this activity, I will be able to:
- Review systemic medications that may be associated with Retinal Toxicity
- Describe ophthalmic testing and abnormalities seen with toxicity
- Review toxicity surveillance strategies – particularly for HydroxyChloroquine
Thomas B. Connor, Jr., MD
Professor of Ophthalmology & Visual Sciences
Medical College of Wisconsin
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved